The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11068 malaria professionals are enjoying the free benefits of MalariaWorld today

amodiaquine

Cross-resistance of the chloroquine-derivative AQ-13 with amodiaquine in Cambodian Plasmodium falciparum isolates

September 23, 2021 - 09:21 -- Open Access
Author(s): 
Nardella F, Mairet-Khedim M, Roesch C, Maher SP, Ke S, Leang R, Leroy D, Witkowski B
Reference: 
J Antimicrob Chemother. 2021 Sep 15;76(10):2565-2568

Expanding resistance to multiple antimalarials, including chloroquine, in South-East Asia (SEA) urges the development of new therapies. AQ-13, a chloroquine derivative, is a new drug candidate for treating malaria caused by Plasmodium falciparum.

The cardiovascular effects of amodiaquine and structurally related antimalarials: An individual patient data meta-analysis

September 8, 2021 - 17:07 -- Open Access
Author(s): 
Chan XHS, Haeusler IL, White NJ, et al.
Reference: 
PLoS Med. 2021 Sep 7;18(9):e1003766

Amodiaquine is a 4-aminoquinoline antimalarial similar to chloroquine that is used extensively for the treatment and prevention of malaria. Data on the cardiovascular effects of amodiaquine are scarce, although transient effects on cardiac electrophysiology (electrocardiographic QT interval prolongation and sinus bradycardia) have been observed. We conducted an individual patient data meta-analysis to characterise the cardiovascular effects of amodiaquine and thereby support development of risk minimisation measures to improve the safety of this important antimalarial.

Not Open Access | Unanticipated CNS Safety Signal in a Placebo-controlled, Randomized Trial of Co-administered Atovaquone-Proguanil and Amodiaquine

September 1, 2021 - 15:48 -- NOT Open Access
Author(s): 
Chalon S, Chughlay MF, Abla N, Tchouatieu AM, Haouala A, Hutter B, Lorch U, Macintyre F
Reference: 
Clin Pharmacol Ther. 2021 Aug 28

Atovaquone-proguanil (ATV-PG) plus amodiaquine (AQ) has been considered as a potential replacement for sulfadoxine-pyrimethamine plus AQ for seasonal malaria chemoprevention (SMC) in African children. This randomized, double-blind, placebo-controlled, parallel group study assessed the safety, tolerability, and pharmacokinetics (PK) of ATV-PG plus AQ in healthy adult males and females of Black sub-Saharan African origin.

Clinical and In Vitro Resistance of Plasmodium falciparum to Artesunate-Amodiaquine in Cambodia

August 4, 2021 - 16:07 -- Open Access
Author(s): 
Mairet-Khedim M, Leang R, Witkowski B, et al.
Reference: 
Clin Infect Dis. 2021 Aug 2;73(3):406-413

Artesunate-amodiaquine is a potential therapy for uncomplicated malaria in Cambodia.

Not Open Access | Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquine

February 9, 2021 - 10:05 -- NOT Open Access
Author(s): 
Kawuma AN, Walimbwa SI, Pillai GC, Khoo S, Lamorde M, Wasmann RE, Denti P
Reference: 
J Antimicrob Chemother. 2021 Feb 7:dkab022

In sub-Saharan Africa, artemisinin-containing therapies for malaria treatment are regularly co-administered with ART. Currently, dolutegravir-based regimens are recommended as first-line therapy for HIV across most of Africa.

Pharmacokinetic profile of amodiaquine and its active metabolite desethylamodiaquine in Ghanaian patients with uncomplicated falciparum malaria

January 9, 2021 - 13:17 -- Open Access
Author(s): 
Thomas A. Anyorigiya, Sandra Castel, Karen I. Barnes, et al.
Reference: 
Malaria Journal 2021 20:18, 6 January 2021

Accurate measurement of anti-malarial drug concentrations in therapeutic efficacy studies is essential to distinguish between inadequate drug exposure and anti-malarial drug resistance, and to inform optimal anti-malarial dosing in key target population groups.

Two-Year Scale-Up of Seasonal Malaria Chemoprevention Reduced Malaria Morbidity among Children in the Health District of Koutiala, Mali

September 16, 2020 - 13:07 -- Open Access
Author(s): 
Maiga H, Gaudart J, Djimde AA, et al.
Reference: 
Int J Environ Res Public Health. 2020 Sep 11;17(18):E6639

Previous controlled studies demonstrated seasonal malaria chemoprevention (SMC) reduces malaria morbidity by >80% in children aged 3-59 months. Here, we assessed malaria morbidity after large-scale SMC implementation during a pilot campaign in the health district of Koutiala, Mali.

Increased Sensitivity of Plasmodium falciparum to Artesunate/Amodiaquine Despite 14 Years as First-Line Malaria Treatment, Zanzibar

August 4, 2020 - 15:31 -- Open Access
Author(s): 
Msellem M, Morris U, Soe A, Abbas FB, Ali AW, Barnes R, Frumento P, Ali AS, Mårtensson A, Björkman A
Reference: 
Emerg Infect Dis. 2020 Aug;26(8):1767-1777

Artemisinin-based combination therapies (ACTs) are first-line treatments for uncomplicated Plasmodium falciparum malaria. ACT resistance is spreading in Asia but not yet in Africa. Reduced effects of ACT partner drugs have been reported but with little information regarding widely used artesunate/amodiaquine (ASAQ).

Plasmodium falciparum genetic factors rather than host factors are likely to drive resistance to ACT in Ghana

July 20, 2020 - 14:50 -- Open Access
Author(s): 
Peter Hodoameda, Nancy Odurowah Duah-Quashie, Charles Oheneba Hagan, Sena Matrevi, Benjamin Abuaku, Kwadwo Koram and Neils Ben Quashie
Reference: 
Malaria Journal 2020 19:255, 15 July 2020

Artemisinin-based combination therapy (ACT) partner drugs, currently used in Ghana are lumefantrine, amodiaquine and piperaquine. Plasmodium falciparum isolates with reduced susceptibility to these partner drugs may affect treatment outcome. Mutations in pfmdr1 gene is linked to reduced parasite susceptibility to amodiaquine and lumefantrine. In addition, the potency of the partner drugs in vivo depends on the metabolism by the cytochrome P450 (CYP) enzyme in the host. Mutations in the CYP2C8 and CYP3A4 genes are linked to reduced metabolism of amodiaquine and lumefantrine in vitro, respectively. This study investigated the host and parasite genetic factors affecting the susceptibility of the malaria parasite to ACT partner drugs.

Adherence and Population Pharmacokinetic Properties of Amodiaquine When Used for Seasonal Malaria Chemoprevention in African Children

May 7, 2020 - 13:24 -- Open Access
Author(s): 
Ding J, Coldiron ME, Assao B, Guindo O, Blessborn D, Winterberg M, Grais RF, Koscalova A, Langendorf C, Tarning J
Reference: 
Clin Pharmacol Ther. 2020 May;107(5):1179-1188

Poor adherence to seasonal malaria chemoprevention (SMC) might affect the protective effectiveness of SMC. Here, we evaluated the population pharmacokinetic properties of amodiaquine and its active metabolite, desethylamodiaquine, in children receiving SMC under directly observed ideal conditions (n = 136), and the adherence of SMC at an implementation phase in children participating in a case‐control study to evaluate SMC effectiveness (n = 869).

Pages

Subscribe to RSS - amodiaquine